56052-26-7

Basic information

• Product Name: (1-BROMONAPHTHALEN-4-YL)METHANOL
• Synonyms: (4-BROMO-NAPHTHALEN-1-YL)-METHANOL;(1-BROMONAPHTHALEN-4-YL)METHANOL;1-Bromo-4-hydroxymethylnaphthalene
• CAS NO: 56052-26-7
• Molecular Formula: C₁₁H₉BrO
• Molecular Weight: 237.09
• Mol File: 56052-26-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: (1-BROMONAPHTHALEN-4-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (1-BROMONAPHTHALEN-4-YL)METHANOL(56052-26-7)
• EPA Substance Registry System: (1-BROMONAPHTHALEN-4-YL)METHANOL(56052-26-7)

Safety Data

• Hazardous Substances Data: 56052-26-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1-BROMONAPHTHALEN-4-YL)METHANOL is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, (1-BROMONAPHTHALEN-4-YL)METHANOL is utilized as a precursor in the production of agrochemicals, aiding in the creation of compounds that can enhance crop protection and yield.
Used in Dye Industry:
(1-BROMONAPHTHALEN-4-YL)METHANOL is employed as a building block in the synthesis of dyes, contributing to the development of novel colorants for various applications, including textiles and printing inks.
Used in Research and Development:
As a reagent in organic synthesis, (1-BROMONAPHTHALEN-4-YL)METHANOL is used in research and development to explore new chemical reactions and pathways, potentially leading to the discovery of innovative compounds and materials.

Upstream product

• 16650-55-8 4-bromonaphthalene-1-carboxylic acid 
• 444913-42-2 (4-bromo-1-naphthyl)methyl acetate 
• 90-11-9 1-Bromonaphthalene 
• 79996-99-9 1-bromo-4-bromomethyl-naphthalene 
• 46258-62-2 1-(4-bromonaphthalen-1-yl)ethanone 

Downstream Products

• 79996-99-9 1-bromo-4-bromomethyl-naphthalene 
• 41014-20-4 4-bromomethyl-1-naphthonitrile 
• 16650-55-8 4-bromonaphthalene-1-carboxylic acid 
• 1093281-19-6 (4-(4-methoxyphenyl)naphthalen-1-yl)methanol 
• 1425052-07-8 C₃₂H₄₄BNO₆Si 
• 1425051-93-9 C₂₆H₃₀BNO₆ 
• 1425051-95-1 C₃₃H₃₄BN₃O₉ 
• 1425052-09-0 C₄₄H₅₃BN₂O₈Si 
• 1425051-97-3 C₃₈H₃₉BN₂O₈ 
• 1425051-98-4 C₄₅H₄₃BN₄O₁₁ 
• 50672-84-9 4-bromo-1-naphthaldehyde 
• 1125812-60-3 methyl 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]naphthalene-1-carboxylate 

Relevant articles and documents

Pd-catalyzed allylative dearomatisation using Grignard reagents

Pd-catalyzed allylative dearomatisation of naphthyl halides is shown to be feasible by employing Grignard reagents. The high reactivity of the nucleophile allows for fast reactions and low catalyst loading, while a plethora of successfully substituted compounds illustrate the broad scope. Five membered heteroaromatic compounds are also demonstrated to be reactive under similar conditions.

Enantioselective α-Benzylation of Acyclic Esters Using π-Extended Electrophiles

The first asymmetric cooperative Lewis base/palladium catalyzed benzylic alkylation of acyclic esters is reported. This reaction proceeds via stereodefined C1-ammonium enolate nucleophiles. Critical to its success was the identification of benzylic phosphate electrophiles, which were uniquely reactive. Alkylated products were obtained with very high levels of enantioselectivity, and this method has been applied toward the synthesis of the thrombin inhibitor DX-9065a.

ANTIPARISITIC AND PESTICIDAL ISOXAZOLINE COMPOUNDS

The present invention relates to novel and inventive isoxazoline of formula (I) and salts thereof: wherein variables D1, D2, D3, D4, D5, R1, B1, B2, B3, R2, R3, R4, R5, R6, Y, Z, L, a and b are described herein are as defined in the description. The invention also relates to parasiticidal and pesticidal compositions comprising the isoxazoline compounds of formula (I), processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

Effects of electronics, aromaticity, and solvent polarity on the rate of azaquinone-methide-mediated depolymerization of aromatic carbamate oligomers

This paper uses physical-organic studies on well-defined oligomers to establish design principles for creating aromatic poly(carbamates) that depolymerize from head-to-tail in low dielectric constant environments when exposed to specific applied signals. We show that either increasing electron density or decreasing the aromaticity of aromatic repeating units in poly(carbamates) increase the overall depolymerization rate. For example, a methoxybenzene-based repeating unit provides depolymerization rates that are 143× faster than oligomers that contain a benzene-based repeating unit. Furthermore, the rate of depolymerization in the methoxybenzene-based system is tolerant to low dielectric environments, whereas the benzene-based oligomers are not.

CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: Synthesis, biological evaluation and molecular modelling

Twenty-one novel compounds originating from two classes of annulated biphenyls were synthesized as mimetics of the steroidal A- and C-rings and examined for their potency as inhibitors of human CYP17. Selected compounds were tested for inhibition of the hepatic CYP enzyme 3A4. Potent CYP17 inhibitors were found for each class, compound 9 (17 and 71% at 0.2 and 2 μM, respectively) and 21 (591 nM). Compound 21 showed only weak inhibition of CYP3A4 (32 and 64% at 2 and 10 μM, respectively). Both compounds, however, exhibited moderate to strong inhibition of the glucocorticoid-forming enzyme CYP11B1. The most interesting compounds were docked into our protein model. They bound into one of the modes which we have previously published. New interaction regions were identified.

AMINOETHANOL DERIVATIVES

The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar1 is an aromatic ring group optionally having substituents, Ar2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.

Preparation of a series of substituted fluoromethylnaphthalenes

A series of 22 3- and 4-substituted 1-fluoromethylnaphthalenes have been synthesized.Details of practical procedures for the preparation of all intermediates are described, and physical properties for all of the substituted naphthalenes synthesized, and spectral parameters for 51 previously unknown compounds, are given.